# Phase II Study of Irinotecan HCI for Recurrent Anaplastic Astrocytomas, Mixed Malignant Gliomas, and Oligodendrogliomas

> **NCT00360828** · PHASE2 · TERMINATED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 10 (actual)

## Conditions studied

- Astrocytoma
- Glioma
- Oligodendroglioma

## Interventions

- **DRUG:** Irinotecan Hydrochloride (HCI) Treatment
- **DRUG:** Continued Irinotecan Hydrochloride (HCI) Treatment

## Key facts

- **NCT ID:** NCT00360828
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-02
- **Primary completion:** 2010-10
- **Final completion:** 2010-10
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Principal Investigator left Moffitt and study had low accrual.
- **Last updated:** 2017-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00360828

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00360828, "Phase II Study of Irinotecan HCI for Recurrent Anaplastic Astrocytomas, Mixed Malignant Gliomas, and Oligodendrogliomas". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00360828. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*